Key facts
- It has raised $3.1M; the latest was Seed Round ($2.9M) in Jun 2025.
- Notable investors include MedTech Innovator, MedTech Angels, Cedars-Sinai Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for FormaPath
- ·The full record, as it builds
Funding rounds
No funding rounds for FormaPath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FormaPath
Developer of automated tools designed to streamline tissue biopsy handling and lymph node isolation for cancer diagnostics. The company offers a hands-free system for biopsy processing and an instrument that automatically separates lymph nodes from adipose tissue, enabling pathology labs and cancer research centers to improve diagnostic accuracy and efficiency.
- Sector
- Healthcare
- HQ
- Ithaca, NY, United States
- Founded
- 2016
- Employees
- 8
- Website
- formapath.com/
- Ownership
- Privately Held (backing)
FormaPath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FormaPath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FormaPath in its N-PORT filings yet. We sweep new filings monthly.